Oncology

Vistogard treats patients who develop life-threatening toxicities within days of receiving cancer drugs.

Fatigue had a strong association with pain intensity and interference in inflammatory bowel disease.

Bendeka was approved for indolent B-cell non-Hodgkin lymphoma that progressed during or within 6 months of treatment with a rituximab regimen.

Eating before bed can have a significant impact on the development of nonalcoholic fatty liver disease.

New treatment option for patients who no longer respond to Xalkori.

An understanding of biosimilars will be essential for patient consults and education.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

Overall survival rate nearly doubles in patients who used aspirin post-diagnosis.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Anemia caused by chemotherapy for lymphoid malignancies improved in patients with non-Hodgkin's lymphoma and multiple myeloma.

Pollutants may accelerate fibrosis, metabolic disease, and liver cancer.

Treatment with bevacizumab and lomustine not found to offer a survival advantage.

Top recent news in cancer drug development.

Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.

Defective DNA repair mechanisms may contribute to Alzheimer's disease.

Researchers confirm antidepressants do not cause recurrence in breast cancer patients treated with tamoxifen.

Experimental personalized peptide cancer vaccine found to extend overall survival.

Top recent news in cancer drug development.

Portrazza plus chemotherapy treats metastatic squamous non-small cell lung cancer in patients who were not previously treated specifically for advanced lung cancer.

Increasing colon cancer awareness could exponentially decrease disease-related deaths.

Opdivo found to improve overall survival compared with other leading cancer therapies.

Tafinlar plus Mekinist found to improve overall survival in unresectable or metastatic BRAF-mutated melanoma.

Latest news in cancer drug development.

Study suggests increasing oxidative stress through with pro-oxidants may prevent metastasis.

Treatment helps reduce infection risk from low white blood cell count in cancer patients receiving chemotherapy.

Novel drug shows promise in chronic lymphocytic leukemia and non-Hodgkin lymphoma refractory or resistant to current chemotherapies.

FDA requests a more thorough review of rociletinib from ongoing trial.

Opdivo shows extended overall survival and fewer adverse events in patients with RCC compared with Afinitor.